June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension
Author Affiliations & Notes
  • Mark Weiss
    Private Practice, Tulsa, OK
  • Brian Levy
    Aerie Pharmaceuticals, Bedminster, NJ
  • Casey Kopczynski
    Aerie Pharmaceuticals, Research Triangle Park, NC
  • Thomas Van Haarlem
    Aerie Pharmaceuticals, Bedminster, NJ
  • Gary Novack
    PharmaLogic Development, Inc., San Rafael, CA
  • Footnotes
    Commercial Relationships Mark Weiss, Aerie (F), Allergan (F), Alcon (F); Brian Levy, Aerie Pharmaceuticals (E); Casey Kopczynski, Aerie Pharmaceuticals, Inc. (E), Aerie Pharmaceuticals, Inc. (P); Thomas Van Haarlem, Aerie Pharmaceuticals, Inc (E); Gary Novack, Aerie (C), Novabay (C), Nicox (C), Clearside (C), Panoptica (C), Ampio (C), Ocularis (C), Forest (C), Merck (C), Acucela (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 754. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark Weiss, Brian Levy, Casey Kopczynski, Thomas Van Haarlem, Gary Novack, AR-13324-CS201 Study Group; Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2013;54(15):754.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: In this first-in-human study, we sought to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution dosed once-daily in the morning. AR-13324 is both a Rho kinase (ROCK) inhibitor and norepinephrine transporter inhibitor thatthat lowers IOP in animal models through a dual mechanism of action, increasing trabecular outflow and decreasing aqueous production.

Methods: Entry criteria for the study included a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), unmedicated or post-washout IOP ≥ 24 mm Hg in one or both eyes at 08:00 hours and ≥ 21 mm Hg at 10:00, 12:00 and 16:00 hours. Enrolled were 85 patients with elevated intraocular pressure in this 7-day, double-masked, randomized, vehicle-controlled, monocular study of 3 doses of AR-13324 or its vehicle.

Results: Mean diurnal IOP at baseline in the 85 enrolled patients was 24.3 to 25.6 mm Hg. After a week of dosing, all active groups experienced IOP reductions that were significantly different from vehicle at all time points (p = 0.018 to <0.001). Peak reduction occurred at 8 hours after the final morning dose, ranged from 6.1 to 7.2 mm Hg relative to baseline, and appeared to be continuing downward. IOP reduction at trough (24 hours after dosing) was 5.6 to 6.3 mm Hg relative to baseline. Mild (+1) to moderate (+2) conjunctival hyperemia was the most prevalent biomicroscopic finding.

Conclusions: AR-13324 0.01% to 0.04% q.d. (AM) produced large reductions in IOP that were statistically and clinically significant and lasted at least 24 hours after dosing, with 0.02% AR 13324 appearing to reach the top of the dose response curve. IOP decreased steadily for 8 hours following dosing, suggesting that peak efficacy may occur beyond 8 hours. The only safety finding of note was dose-related ocular hyperemia that declined in incidence and severity with repeated dosing. AR-13324, with its dual mechanism of action, shows promise as a novel ocular hypotensive agent for the treatment of glaucoma.

Keywords: 568 intraocular pressure  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.